Compare FLYW & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLYW | NAMS |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 2021 | 2022 |
| Metric | FLYW | NAMS |
|---|---|---|
| Price | $17.13 | $22.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $16.21 | ★ $46.75 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 450.00 | 32.81 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $623,025,000.00 | $22,503,000.00 |
| Revenue This Year | $19.68 | $17.96 |
| Revenue Next Year | $15.25 | $540.65 |
| P/E Ratio | $577.67 | ★ N/A |
| Revenue Growth | ★ 26.59 | N/A |
| 52 Week Low | $10.55 | $21.02 |
| 52 Week High | $19.73 | $42.21 |
| Indicator | FLYW | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 39.85 | 35.55 |
| Support Level | $17.09 | N/A |
| Resistance Level | $19.02 | $37.29 |
| Average True Range (ATR) | 0.62 | 1.41 |
| MACD | -0.16 | -0.07 |
| Stochastic Oscillator | 15.61 | 25.44 |
Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.